Ilya Rachman
Algemeen Directeur bij IMMIX BIOPHARMA, INC.
Vermogen: 2 M $ op 30-04-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Gabriel Morris | M | 38 |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | 3 jaar |
Magda Marquet | M | 65 | 3 jaar | |
Jane Buchan | M | 60 | 3 jaar | |
Carey Ng | M | 45 | 5 jaar | |
Helen Adams | F | 65 | 3 jaar | |
Yekaterina Chudnovsky | F | 39 | 1 jaar | |
Ed Borkowski | M | 64 |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | 1 jaar |
Jeffrey Cooper | M | 68 |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | 1 jaar |
Henry McKinnell | M | 81 |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | 1 jaar |
Mary Coleman | M | 80 |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | 1 jaar |
Jason Hsu | M | 50 | 11 jaar | |
Nandan Oza | M | 61 | 7 jaar | |
Graham Ross | M | 64 | 3 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Vladimir Torchilin | M | 77 | - | |
Sean Senn | M | - | - | |
Ryan Witt | M | - | 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 16 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Ilya Rachman
- Persoonlijk netwerk